Month: February 2024

ADCs Pipeline Update: Sutro Biopharma Presents Encouraging Data in Patients with Advanced Ovarian Cancer

Sutro Biopharma, a California based, clinical-stage company, announced initial safety data in ovarian cancer patients from its ongoing phase I study (NCT03748186) of STRO-002. The drug is a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC) and potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models. Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused

Cell Therapy Pipeline Update: Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial

Cell Therapy pipeline update, Talaris Therapeutics, a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY, announced the initiation of FREEDOM-1 (NCT03995901), the company’s Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients. What is the objective of the trial: This pivotal trial will evaluate the safety and efficacy of a

CARsgen anti-BCMA CAR T CellTherapy Receives RMAT Designation

On 28 October 2019, CARsgen Therapeutics, a clinical-stage biopharma company, announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. What is CT-053: CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of relapsed and/or refractory multiple

Genome Editing Market Update: Intellia Therapeutics Presents Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy

Intellia Therapeutics, one of the leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) meeting taking place October 22-25, 2019, in Barcelona, Spain. The global genome

Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities

The application of digital twins in healthcare has the potential to revolutionize patient care, improve clinical outcomes, and reduce costs. Digital twins, or virtual replicas of physical objects and environments, are being used in many different industries, and healthcare is no exception. In healthcare, these can be used to provide better patient monitoring, improve remote

Adeno-Associated Viral Vectors: Unlocking the Future Opportunities

Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level,  the gene therapy market has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion capital

NFC Tags and RFID Smart Labels for Pharmaceutical and Healthcare Industry: Lets trace medicines from its origin

Traditionally, text and images were printed on pharmaceutical products to convey important information. In recent years, the use of smart labels allows the developer to convey a greater amount of information about the product to the consumers, without the need for additional packaging space. It is worth noting that smart labels contain a transponder code

Gene Therapy Pipeline Update: AGTC Presents Promising Data of its AAV Vectors for Ocular Gene Therapy

Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, developing transformational genetic therapies for patients suffering from rare and debilitating diseases, announced new data from non-clinical studies evaluating the effect of pre-existing anti-AAV antibodies on the transduction and expression efficiency of AAV vectors. Presently, over 250 companies are engaged in the gene therapy pipeline, the gene

Prescription Digital Therapeutics: Advancing Access to the Digital Pills

As per United Nation’s report, the current global population stands at around 8 billion and expected to reach 9 billion by the end of 2030. This increase in population is accompanied with a rise in the incidence of several chronic disease indications. In fact, as per a report published by National Association of Chronic Disease

Bioconjugation of Molecules: A Novel Advancement in Therapeutics

Bioconjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. These molecules can be conjugated with various modalities, such as haptens, enzymes, isotopes, fluorescent tags, carrier proteins, polymers, particle conjugates and photoreactive molecules. Bioconjugation is a subset of

Antibody Drug Conjugates Market Update: Ambrx and NovoCodex Collaborate

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period. What is the focus of the agreement: Under the agreement, Ambrx and NovoCodex will

Cybersecurity in Healthcare: A Must Have in Today’s Digital World

The healthcare industry has been amongst the prime targets for hackers over the last several years. In 2017, the healthcare industry had been compromised a number of times, representing 25% of the total number of breaches worldwide. Across these instances, around 31 million records were compromised, stolen or lost. In order to overcome these challenges,

Viral Vector Manufacturing: Current Landscape and Opportunities

Over the last few decades, various viral vector manufacturing have been developed, optimized and standardized for introduction of therapeutic DNA / gene of interest into a patient’s body / cells. Currently, the most popular viral vectors, on the basis of their use in active clinical trials, are those based on AAV, adenovirus, lentivirus and retrovirus.

Myeloid Cell Targeting Therapies: Budding Therapy Against Cancer

The global cancer burden is increasing rapidly with over 19 million new cancer cases and 10 million deaths reported in the year 2020. Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases using cell and gene therapy solutions. With several programs having entered the clinical

New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030

Cancer Therapies continues to be one of the most active segments within the pharmaceutical industry. However, certain biological targets have long eluded drug development efforts. One such target is Ras family, which has been identified to play a critical role in oncogenesis. Scientific literature suggests that the RAS gene is mutated across about 30% of

Outsourcing Antibody Discovery Process: The Profit-Driven Approach to Research

Imagine a world where scientists work together to create special “soldiers” in our bodies called antibodies. These heroes help to fight diseases. Sometimes, scientists ask for help from experts who are really good at finding and designing these antibodies. These experts are like the superhero squad for medical research. They provide their antibody discovery services

Advanced Wound Care Products: The Novel Wound Care and Management Products

The rising prevalence of chronic diseases has resulted in rise in the associated co-morbidities, including wounds, mental health disorders, vascular disorders, sensory impairments, and others. Among these, the management of wounds has emerged as a critical aspect within the healthcare sector. Presently, more than 15 million individuals worldwide are suffering from various types of wounds,

Industrial and Medical Exoskeleton: Current Landscape and Future Market Outlook

Originally used in biology, the term exoskeleton refers to a chitinous or calcified external skeleton used by various animal taxa for structural support and defense against predators. Drawing from a similar concept, in the field of robotics, exoskeletons are wearable electromechanical devices that have been developed as augmentative devices to enhance the physical performance of

Cold Chain Packaging – Current Scenario and Future Potential

Cold chain is a three-fold concept, involving certain aspects that can be co-related to science, technology, and process development. In terms of science, cold chain industry requires the understanding of chemical and biological processes associated with the product. This technology usually relies on physical methods to ensure desirable temperature conditions for perishable products throughout the